Cargando…
THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly
Disclosure: C.M. Falch: Speaker; Self; Pfizer, Inc. K. Godang: None. T. Lekva: None. A. Heck: Speaker; Self; Ipsen, Recordati. J. Bollerslev: Advisory Board Member; Self; Pfizer, Inc. Speaker; Self; Ipsen, Pfizer, Inc. N.C. Olarescu: Speaker; Self; Pfizer, Inc., CORE2ED. Objective: Patients with act...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553874/ http://dx.doi.org/10.1210/jendso/bvad114.1147 |
_version_ | 1785116277635809280 |
---|---|
author | Falch, Camilla Maria Godang, Kristin Lekva, Tove Heck, Ansgar Bollerslev, Jens Olarescu, Nicoleta Cristina |
author_facet | Falch, Camilla Maria Godang, Kristin Lekva, Tove Heck, Ansgar Bollerslev, Jens Olarescu, Nicoleta Cristina |
author_sort | Falch, Camilla Maria |
collection | PubMed |
description | Disclosure: C.M. Falch: Speaker; Self; Pfizer, Inc. K. Godang: None. T. Lekva: None. A. Heck: Speaker; Self; Ipsen, Recordati. J. Bollerslev: Advisory Board Member; Self; Pfizer, Inc. Speaker; Self; Ipsen, Pfizer, Inc. N.C. Olarescu: Speaker; Self; Pfizer, Inc., CORE2ED. Objective: Patients with active acromegaly present a decreased adipose tissue (AT) mass, and short-term studies show that the AT increases following treatment. However, it remains unclear if the increase is persistent in the long-term perspective. Aim: To characterize the depot specific changes of AT after treatment of acromegaly and identify contributing factors. Methods: In a clinically well-defined cohort of patients with acromegaly (n = 62), visceral (VAT), subcutaneous (SAT), total (TAT) adipose tissue, and android to gynoid ratio (A/G ratio) were measured by Dual Energy X-ray Absorptiometry (DXA). Measurements were assessed at diagnosis, and at a short- and long-term visit (median follow-up time (IQR): 1.9 (1.5-2.3) and 5.5 (3.6-9.6) years, respectively). Growth hormone (GH), insulin-like growth factor I (IGF-I), glucose and HbA1c levels, gonadal status, and the presence of diabetes mellitus were recorded prospectively. Remission status was assessed at the long-term visit (IGF-I ≤ 1.3 x ULN). Comparison between time points was performed using paired t-test or Mann-Whitney U test depending on distribution, and chi-square test for categorical variables. Differences in the temporal course were evaluated by mixed model analyses, adjusted for age. Results: VAT and A/G ratio increased at both time points, whereas SAT and TAT mainly increased at short-term, plateauing afterwards (p < 0.05 for all). VAT and A/G ratio were higher in men (p = 0.035 and p < 0.001), and the A/G ratio increased more compared to women (p = 0.003). BMI remained stable. Glucose and HbA1c decreased at short-term (p < 0.05) and remained stable at long-term, with no obvious sex differences. The gonadal status had no effect on the increase in AT in women. The increase in VAT (p = 0.046), but not SAT, TAT or A/G ratio, was more pronounced in patients with diabetes mellitus. The increase in AT strongly correlated with the decrease in GH (SAT (R = -0.48), TAT (R = -0.51), p < 0.001 for both) and IGF-I (VAT (R = -0.28, p = 0.036), SAT (R = -0.27, p = 0.046), TAT (R = -0.26, p = 0.048) at long-term. The decrease in glucose correlated with the decrease in HbA1c (R = 0.38, p = 0.009) and IGF-I (R = 0.32, p = 0.014) at long-term. Remission status had no effect on changes in AT mass during follow-up. Conclusion: Treatment of acromegaly leads to an increase in AT mass in a depot and sex specific manner both at short-term and long-term follow-up. Glucose metabolism improves rapidly after disease control and persists, whereas patients with diabetes mellitus have a higher VAT increase that may worsen their long-term metabolic outcome. Presentation: Thursday, June 15, 2023 |
format | Online Article Text |
id | pubmed-10553874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105538742023-10-06 THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly Falch, Camilla Maria Godang, Kristin Lekva, Tove Heck, Ansgar Bollerslev, Jens Olarescu, Nicoleta Cristina J Endocr Soc Neuroendocrinology And Pituitary Disclosure: C.M. Falch: Speaker; Self; Pfizer, Inc. K. Godang: None. T. Lekva: None. A. Heck: Speaker; Self; Ipsen, Recordati. J. Bollerslev: Advisory Board Member; Self; Pfizer, Inc. Speaker; Self; Ipsen, Pfizer, Inc. N.C. Olarescu: Speaker; Self; Pfizer, Inc., CORE2ED. Objective: Patients with active acromegaly present a decreased adipose tissue (AT) mass, and short-term studies show that the AT increases following treatment. However, it remains unclear if the increase is persistent in the long-term perspective. Aim: To characterize the depot specific changes of AT after treatment of acromegaly and identify contributing factors. Methods: In a clinically well-defined cohort of patients with acromegaly (n = 62), visceral (VAT), subcutaneous (SAT), total (TAT) adipose tissue, and android to gynoid ratio (A/G ratio) were measured by Dual Energy X-ray Absorptiometry (DXA). Measurements were assessed at diagnosis, and at a short- and long-term visit (median follow-up time (IQR): 1.9 (1.5-2.3) and 5.5 (3.6-9.6) years, respectively). Growth hormone (GH), insulin-like growth factor I (IGF-I), glucose and HbA1c levels, gonadal status, and the presence of diabetes mellitus were recorded prospectively. Remission status was assessed at the long-term visit (IGF-I ≤ 1.3 x ULN). Comparison between time points was performed using paired t-test or Mann-Whitney U test depending on distribution, and chi-square test for categorical variables. Differences in the temporal course were evaluated by mixed model analyses, adjusted for age. Results: VAT and A/G ratio increased at both time points, whereas SAT and TAT mainly increased at short-term, plateauing afterwards (p < 0.05 for all). VAT and A/G ratio were higher in men (p = 0.035 and p < 0.001), and the A/G ratio increased more compared to women (p = 0.003). BMI remained stable. Glucose and HbA1c decreased at short-term (p < 0.05) and remained stable at long-term, with no obvious sex differences. The gonadal status had no effect on the increase in AT in women. The increase in VAT (p = 0.046), but not SAT, TAT or A/G ratio, was more pronounced in patients with diabetes mellitus. The increase in AT strongly correlated with the decrease in GH (SAT (R = -0.48), TAT (R = -0.51), p < 0.001 for both) and IGF-I (VAT (R = -0.28, p = 0.036), SAT (R = -0.27, p = 0.046), TAT (R = -0.26, p = 0.048) at long-term. The decrease in glucose correlated with the decrease in HbA1c (R = 0.38, p = 0.009) and IGF-I (R = 0.32, p = 0.014) at long-term. Remission status had no effect on changes in AT mass during follow-up. Conclusion: Treatment of acromegaly leads to an increase in AT mass in a depot and sex specific manner both at short-term and long-term follow-up. Glucose metabolism improves rapidly after disease control and persists, whereas patients with diabetes mellitus have a higher VAT increase that may worsen their long-term metabolic outcome. Presentation: Thursday, June 15, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10553874/ http://dx.doi.org/10.1210/jendso/bvad114.1147 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Neuroendocrinology And Pituitary Falch, Camilla Maria Godang, Kristin Lekva, Tove Heck, Ansgar Bollerslev, Jens Olarescu, Nicoleta Cristina THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly |
title | THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly |
title_full | THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly |
title_fullStr | THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly |
title_full_unstemmed | THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly |
title_short | THU067 Long-term Depot Specific Changes In Adipose Tissue After Treatment Of Acromegaly |
title_sort | thu067 long-term depot specific changes in adipose tissue after treatment of acromegaly |
topic | Neuroendocrinology And Pituitary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553874/ http://dx.doi.org/10.1210/jendso/bvad114.1147 |
work_keys_str_mv | AT falchcamillamaria thu067longtermdepotspecificchangesinadiposetissueaftertreatmentofacromegaly AT godangkristin thu067longtermdepotspecificchangesinadiposetissueaftertreatmentofacromegaly AT lekvatove thu067longtermdepotspecificchangesinadiposetissueaftertreatmentofacromegaly AT heckansgar thu067longtermdepotspecificchangesinadiposetissueaftertreatmentofacromegaly AT bollerslevjens thu067longtermdepotspecificchangesinadiposetissueaftertreatmentofacromegaly AT olarescunicoletacristina thu067longtermdepotspecificchangesinadiposetissueaftertreatmentofacromegaly |